BackIntech Biopharm Overview
Intech Biopharm Corporation

Intech Biopharm P/E Ratio

Latest P/E ratio for Intech Biopharm: -5.5 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-5.50

P/E Ratio

-5.50

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Intech Biopharm (6461.TWO) FAQ

The latest P/E ratio for 6461.TWO is -5.5. That is below the Healthcare sector average of 21.65. Investors often review this figure alongside Intech Biopharm's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, 6461.TWO currently prints -5.5 for P/E ratio, while the sector average sits near 21.65. That is roughly 125.4% below the sector mean. Large gaps often invite a closer look at Intech Biopharm's growth, margins, and balance sheet.

A P/E ratio of -5.5 for Intech Biopharm is not 'good' or 'bad' on its own. Compare it with the peer average (21.65) and with 6461.TWO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting 6461.TWO's P/E ratio (-5.5), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Intech Biopharm's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.